Navigation Links
MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
Date:10/27/2007

SAN FRANCISCO, October 26, 2007 MedImmune, Inc. today announced it will present three abstracts at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, adding to the companys growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of hospitalization among infants.

MedImmune is pleased to present data that provide key insights into how we can optimize the fight against RSV, said Jessie R. Groothuis, M.D., vice president, medical and scientific affairs, infectious disease. Cost-effectiveness data help insurers, governments, and families understand the benefits of RSV prophylaxis and the potential impact of not taking preventive measures. Surveillance data help us understand local variants in RSV outbreaks, which can inform and improve RSV prevention guidelines.

MedImmune abstracts to be presented at AAP include:

  • Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab Among Preterm Infants After Valuing a Reduction in Persistent Wheezing (Poster #P14) Mark J. Polak, M.D., Saturday, October 27th, 2007 from 12:15 1:00 p.m.

    BACKGROUND: Recent trials have suggested that Synagis (palivizumab), a monoclonal antibody (MAb) that is the standard of care in RSV prevention, reduced the incidence of persistent wheezing in studied populations. Researchers conducted a cost-effectiveness analysis of prophylaxis with Synagis compared with no prophylaxis among preterm infants less than 32 weeks and between 32 and 35 weeks gestation, factoring in the quality of life associated with a reduction in persistent wheezing.

  • A Nationwide Hospital RSV Surveillance Program: Interim Assessment of the 2006-2007 RSV Season (Poster #P25) Marnie L. Boron, PharmD, Saturday, October 27th, 2007 from 12:15 1:00 p.m.

    BACKGROUND: Due to limited uniformity in RSV testing and local surveillance reporting, nationwide RSV prevention programs are not optimal. A nationwide surveillance program was initiated to track and report RSV activity at the local level in a timely manner. This abstract includes an interim report of the data collected to date.

  • Regional Respiratory Syncytial Virus Surveillance Data for Georgia and Implications for Prophylactic Administration of Palivizumab (Poster #P32) Mark Eggleston, PharmD, MBA, Saturday, October 27th, 2007 from 12:15 1:00 p.m.

    BACKGROUND: The Georgia Division of Public Health initiated an RSV surveillance program in mid-2000 to monitor RSV activity within four regions of the state. This study aimed to identify the onset, duration, and peak month of the RSV season in each of the four regions and evaluate whether national guidelines for RSV prophylaxis with Synagis are sufficient or whether recommendations should be based on local RSV virology data.


'/>"/>

Contact: Tor Constantino
301-398-5801
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President ... later this year. Dyer started as the Chairman of the Management Committee when ... of the corporation including the recruitment of investor/owners and development of the business plan. ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: